BDTX vs. TYRA, KURA, MGTX, MNMD, BCYC, BCAX, DNA, ZVRA, VALN, and MAZE
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Tyra Biosciences (TYRA), Kura Oncology (KURA), MeiraGTx (MGTX), Mind Medicine (MindMed) (MNMD), Bicycle Therapeutics (BCYC), Bicara Therapeutics (BCAX), Ginkgo Bioworks (DNA), Zevra Therapeutics (ZVRA), Valneva (VALN), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs. Its Competitors
Tyra Biosciences (NASDAQ:TYRA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.
Tyra Biosciences presently has a consensus target price of $30.83, suggesting a potential upside of 208.49%. Black Diamond Therapeutics has a consensus target price of $12.80, suggesting a potential upside of 396.12%. Given Black Diamond Therapeutics' higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Tyra Biosciences.
In the previous week, Tyra Biosciences had 3 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 6 mentions for Tyra Biosciences and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.40 beat Tyra Biosciences' score of 0.03 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 15.2% of Tyra Biosciences shares are held by company insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Tyra Biosciences is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500.
Black Diamond Therapeutics' return on equity of 4.70% beat Tyra Biosciences' return on equity.
Summary
Black Diamond Therapeutics beats Tyra Biosciences on 9 of the 12 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 7/4/2025 by MarketBeat.com Staff
Free BDTX Stock Alerts